Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.
Ferrata Storti Foundation
MetadataShow full item record
Grinfeld, J., Nangalia, J., & Green, T. (2017). Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.. Haematologica, 102 7-17. https://doi.org/10.3324/haematol.2014.113845
The myeloproliferative neoplasms are a heterogeneous group of clonal disorders characterized by the overproduction of mature cells in the peripheral blood, together with an increased risk of thrombosis and progression to acute myeloid leukemia. The majority of patients with Philadelphia-chromosome negative myeloproliferative neoplasms harbor somatic mutations in Janus kinase 2, leading to constitutive activation. Acquired mutations in calreticulin or myeloproliferative leukemia virus oncogene are found in a significant number of patients with essential thrombocythemia or myelofibrosis, and mutations in numerous epigenetic regulators and spliceosome components are also seen. Although the cellular and molecular consequences of many of these mutations remain unclear, it seems likely that they interact with germline and microenvironmental factors to influence disease pathogenesis. This review will focus on the determinants of specific myeloproliferative neoplasm phenotypes as well as on how an improved understanding of molecular mechanisms can inform our understanding of the disease entities themselves.
Animals, Humans, Myeloproliferative Disorders, Disease Susceptibility, Receptors, Cytokine, Environment, Signal Transduction, Gene Expression Regulation, Phenotype, Mutation, Biomarkers
External DOI: https://doi.org/10.3324/haematol.2014.113845
This record's URL: https://www.repository.cam.ac.uk/handle/1810/264247